Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELROSE: Mechanisms of resistance to first-line osimertinib in EGFR-mutated advanced NSCLC
2018-003218-42Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by CHU de Nantes. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003218-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003218-42.